ADR Biomedical Holdings Inc.
Notice Regarding Dissolution and Liquidation of Specified Subsidiary “Dewey Co., Ltd.”
The company resolved to dissolve and liquidate the specified subsidiary Dewey Co., Ltd. As a business restructuring, the real estate management business will be terminated, and liquidation is expected to be completed in late December 2026. The impact on consolidated results is expected to be minor, but any new material developments will be disclosed.
Key Figures
- Dissolution resolution date: 2026-09-30
- Expected liquidation completion date: Late December 2026 (expected)
- Capital relationship: Parent company 100% ownership
AI要約
Overview of the Dissolution
The Board of Directors resolved to dissolve and liquidate the specified subsidiary Dewey Co., Ltd. The business engages in real estate sales and management. The Group is concentrating management resources on its medical business, and the decision was made considering changes in the business environment and future profitability. It is stated that the company is 100% owned by the parent, and capital relationships, personnel relationships, and transaction relationships are specified.
Outlook and Impact
The schedule for dissolution and liquidation is as follows: the dissolution resolution date is September 30, 2026, and the expected liquidation completion date is late December 2026 (expected). Procedures will be carried out in accordance with applicable laws and regulations. The Company expects the impact on consolidated results to be minor, and there are no revisions to the consolidated earnings guidance for the fiscal year ending March 2027. If any matters that would have a material impact on performance are identified, they will be disclosed promptly.
ADR Biomedical Holdings Inc.
Company overview · Stock price · Financial data · All IR
